JCOG

The Japan Clinical Oncology Group (JCOG) is the largest Japanese cooperative group funded primarily by the National Cancer Center Research and Development Fund.

BSTTSG:Bone and Soft Tissue Tumor Study Group / Publications

更新日:2013年11月8日

a. 論文

1. 委員会承認の治療研究

K Tanaka, Y Iwamoto, et al.:Soft-tissue Sarcomas in the Extremities: Japan Clinical Oncology Group Study JCOG0304. Jpn J Clin Oncol.39(4):271-273,2009.

2. グループ代表者管理の治療研究

Y Iwamoto, et al.:Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.J Orthop Sci. 14(4):397-404,2009.

3. 附随研究等

Y Oda, Y Iwamoto, et al.:Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma.Int J Cancer. 124(8):1852-1859,2009.
U Yamaguchi, H Chuman, et al.:Functional genome screen for therapeutic targets of osteosarcoma. Cancer Sci. 100(12):2268-2274,2009.
T Tsukahara, T Wada, et al.:Scythe/BAT3 regulates apoptotic cell death induced by papillomavirus binding factor in human osteosarcoma. Cancer Sci. 100(1):47-53,2009.
C Fukukawa, J Toguchida, et al.:Activation of the non-canonical Dvl-Rac1-JNK pathway by Frizzled homologue 10 in human synovial sarcoma. Oncogene. 28(8):1110-1120,2009.
K Kohashi, Y Iwamoto, et al.: Reduced expression of SMARCB1/INI1 protein in synovial sarcoma. Mod. Pathol. (23): 981-990, 2010.
S Takenaka, N Araki, et al.: Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo. Int J Oncol. 36:823-831, 2010.
R Nakayama, H Morioka, et al.: Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type. Am J Surg Pathol. 34(11):1599-1607, 2010.
T Shimizu, H Morioka, et al.: c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene. 29(42): 5687-5699, 2010.
R Nakayama, J Toguchida, et al.: Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type. Am J Surg Pathol. 34(11):1599-1607, 2010.
S Iwata, S Tatezaki, et al.: Polycomb group molecule PHC3 regulates polycomb complex composition and prognosis of osteosarcoma. Cancer Sci. 101:1646-1652, 2010.
T Sasaki, T Ozaki, et al.: Preclinical Evaluation of Telomerase - Specific Oncolytic Virotherapy for Human Bone and Soft Tissue Sarcomas. Clin Cancer Res. 17(7):1828-1838, 2011.
M Furu, J Toguchida, et al.: Identification of AFAP1L1 as a prognostic marker for spindle cell sarcomas. Oncogene. 30:4015-4025, 2011.
N Setsu, S Matsuda, Y Iwamoto, et al.: The Akt/Mammalian Target of Rapamycin Pathway Is Activated and Associated With Adverse Prognosis In Soft Tissue Leiomyosarcomas. Cancer. 15;118(6):1637-1648, 2012.
N Setsu, Y Iwamoto, et al.: Inhibin-α and synaptophysin immunoreactivity in synovial sarcoma with granular cell features . Hum Pathol. 43(6):850-857, 2012.
WT van der Graaf, N Araki, et al.: EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 19;379(9829):1879-1886, 2012.
S Kawaguchi, J Toguchida, et al.:SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the Japanese Musculoskeletal Oncology Group. Cancer Sci. 103(9):1625-1630, 2012.
T Nakamura, A Matsumine, et al.: Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma. Cancer. 118:1055-1061, 2012.
H Shibuya, Y Nishida, et al.: Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. Cancer Sci. 103(9):1656-1664, 2012.
M Tomonaga, H Yoshikawa, et al.: Activation of nuclear factor-kappa B by linear ubiquitin chain assembly complex contributes to lung metastasis of osteosarcoma cells. Int J Oncol. 40:409-417, 2012.
M Endo, Y Iwamoto, et al.: Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res. 19(2):450-461, 2013.
Y Fujiwara-Okada, Y Iwamoto, et al.: Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma. Br J Cancer. 5; 108(4):836-847, 2013.
N Setsu, Y Iwamoto, et al.: Phosphorylation of signal transducer and activator of transcription 3 in soft tissue leiomyosarcoma is associated with a better prognosis. Int J Cancer. 132(1):109-115, 2013.

4. 総説・解説

J Toguchida , et al.:Molecular genetics of sarcomas: Applications to diagnoses and therapy. Cancer Sci. 100(9):1573-1580, 2009.
N Naka, N Araki, et al.: Synovial sarcoma is a stem cell malignancy. Stem Cells. 28:1119-1131, 2010.
岩本幸英: 悪性骨腫瘍、整形外科専門医テキスト、南江堂. 東京. 365-372, 2010.
松本嘉寛、岩本幸英、他: 進行骨肉腫例に対するsecond-line chemotherapyと新規薬剤療法の開発?現状と展望 整形外科. 61巻8号: 815-820, 2010.
小田義直、岩本幸英、他: 生検標本による軟部肉腫の組織型・悪性度判定における病理診断の問題点, 日整会誌. 84:1114-1119, 2010
森岡秀夫、他: 軟部腫瘍の診断と治療,臨床整形外科. 45: 209-213, 2010.
川口哲、和田卓郎: 骨・軟部肉腫のペプチドワクチン療法、整形外科. 61:714-719, 2010.
蛭田啓之、松本誠一、他: 骨肉腫術前化学療法の組織学的効果判定、整形外科. 61(8):764-768, 2010.
田仲和宏: 非円形細胞軟部肉腫に対する化学療法. 整形外科, 61:821-825, 2010.
大野貴敏: 悪性軟部腫瘍の治療、臨床整形外科. 第45巻第3号:235-240, 2010.
中馬広一: 3章 骨肉腫. 小児がん診療ガイドライン2011年版. 金原出版, 97-137, 2011
蛭田啓之、松本誠一、他:軟部肉腫の組織学的治療効果判定と切除縁評価. 軟部腫瘍、腫瘍病理鑑別診断アトラス. 文光堂, 246-254, 2011.
Y Iwamoto, K Tanaka.: The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 42:467-470, 2012.
田仲和宏: 悪性軟部腫瘍における化学療法の意義. 癌と化学療法, 39:378-380, 2012.
平賀博明: 悪性骨腫瘍; 骨・軟部腫瘍、新臨床腫瘍学 改訂第3版、南江堂、東京, 489-493, 2012.
比留間徹: 骨軟部腫瘍の化学療法、がん化学療法, 66-69, 2012.

b. 主な学会発表

1. 委員会承認の治療研究

田仲和宏、岩本幸英 :JCOG骨軟部腫瘍グループにおける「高悪性度非円形細胞軟部肉腫に対するIFO+ADRによる術前術後補助化学療法の第Ⅱ相臨床試験」.第40回日本整形外科学会骨・軟部腫瘍学術集会. 2007年7月.
K Tanaka, Y Iwamoto, et al.: Adjuvant and neoadjuvant chemotheraddy (NAC) with ifosfamide (IFO) and Adriamycin (ADM) for high-grade soft tissue sarcomas (STS) in the extremities: Japan Clinical Oncology Group Study JCOG0304. Annual Meeting of American Society of Clinical Oncology. Jun 2011.
田仲和宏、岩本幸英、他: 軟部肉腫に対する化学療法の多施設共同臨床試験(JCOG study). 第85回日本整形外科学会学術総会. 2012年5月.

2. グループ代表者管理の治療研究

なし  

3. 附随研究等

R Niimi, A Matsumine, et al.: Expression of SAP97 as a biomarker of outcome in malignant fibrous histiocytomas. The 55th Annual Meeting of the Orthopaedic Research Society. Feb 2009.
Y Morimoto, T Ozaki, et al.: Response Evaluation Criteria in Solid Tumor (RECIST) in Soft Tissue Sarcoma of Extremity.The 15th Annual Meeting of Connective Tissue Oncology Society. Nov 2009.
Y Okada, Y Iwamoto, et al.: Y-box binding protein-1 regulates cell proliferation and associates with clinical prognosis of osteosarcoma. The Orthopaedic Research Society 2011 Annual Meeting. Jan 2011.
N Naka: Synovial sarcoma is a stem cell malignancy. The 7th Combined meeting of the Orthopaedic Research Societies. Oct 2010.
Y Morimoto, T Ozaki, et al.: SNP in FGFR4 at codon 388 is still correlated with overall survival in high-grade soft tissue sarcoma over five years followup. 16th Annual Meeting of the Connective Tissue Oncology Society. Nov 2010.
E Kobayashi, H Morioka, et al.: Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. 8th Asia Pacific Musculoskeletal Tumor Society Meeting. Feb 2010.
T Tsukahara, T Wada, et al.: Scythe/BAT3 regulates apoptotic cell death induced by the osteosarcoma antigen PBF in human osteosarcoma. 16th Annual Meeting of the Connective Tissue Oncology Society. Nov 2010.
S Kawaguchi, T Wada, et al.: Clinical and immunologic responses of synovial sarcoma patients treated with SYT-SSX fusion gene-derived peptide vaccines. 16th Annual Meeting of the Connective Tissue Oncology Society. Nov 2010.
S Tamaki, J Toguchida, et al.: Genetic and epigenetic regulation of synovial sarcoma-associated molecule, FZD10. 16th Annual Meeting of the Connective Tissue Oncology Society. Nov 2010.
K Hori, A Matsumine, et al.: Clinical outcome of Mie Osteosarcoma Study Protocol (MOS protocol) in the treatment of osteosarcoma patient. 8th Asia Pacific Musculoskeletal Tumor Society Meeting. Feb 2010.
N Hashimoto, H Yoshikawa, et al.: A Phase I/II Study of Immunotherapy Targeting WT1 Peptide in Patients with Advanced/Metastatic Bone and Soft-tissue Sarcomas. 16th Annual Meeting of the Connective Tissue Oncology Society. Nov 2010.
T Tanizawa, S Matsumoto et al.: Clinical outcome of Synovial Sarcoma cases. 8th Asia Pacific Musculoskeletal Tumor Society Meeting. Feb 2010.
T Sasaki, T Ozaki, et al.: Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas. 2011 Connective Tissue Oncology Society (CTOS) / Musculoskeletal Tumor Society(MSTS) combined meeting. Oct 2011.
K Horiuchi, H Morioka, et al.: A novel multi-kinase inhibitor, Pazopanib, suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway. 17th Annual Meeting of the Connective Tissue Oncology Society. Oct 2011.
T Matsubara, A Matsumine, et al.: Clinical outocome of acridine orange therapy supported by photodynamic surgery and radiodynamic therapy for soft tissue sarcomas, compared with conventional limb salvage surgery after wide resection. 16th International Symposium on Limb Salvage. Sep 2011.
K Asanuma, A Matsumine, et al.: Tissue factor mRNA expression in 78 soft tissue sarcoma patients. 16th International Symposium on Limb Salvage. Sep 2011.
S Matsumoto:Long-tern results of "in situ preparation" for soft tissue sarcoma. 24th Annual Meeting of the European Musculo-Skeletal Oncology Society. May 2011.
K Hayakawa, J Toguchida, et al.: Application of iPS cell technology for the analysis of origin-unknown sarcoma characterized by a specific fusion gene. The 17th Annual Meeting of the Connective Tissue Oncology Society (CTOS). Nov 2012.
J Hasei, T Ozaki, et al.: p53-mediated apoptotic signaling overcomes the resistance to oncolytic adenovirus in human osteosarcoma cells. 104th Annual Meeting of American Association for Cancer Research (AACR). Apr 2012.
K Yamada, T Ohno, et al.: Forced expression of EWS-ATF1 induces soft tissue sarcomas 2012 Annual Meeting of the Orthopaedic Research Society. Feb 2012.
E Kobayashi, H Morioka, et al.: MicroRNA expression and functional profiles of osteosarcoma. The 17th Annual Meeting of the Connective Tissue Oncology Society(CTOS). Nov 2012

4. 総説・解説

Y Iwamoto: Recent advance in the treatment of bone and soft tissue sarcomas. The combined academic conference of 16th Asia-Pacific Orthopaedic Association (APOA) and the 59th Annual meeting of Taiwan Orthopaedic Association (TOA). Nov 2010.
J Toguchida, et al.: In vivo tumor forming-signature of human osteosarcoma cells revealed by genome-wide expression profiling. 8th International Society for Stem Cell Research. Jun 2010.
尾﨑敏文:骨・軟部腫瘍におけるこの10 年の進歩と将来への展望. 第115回中部日本整形外科災害外科学会. 2010年10月.
戸口田淳也: 肉腫の分子生物学. 第83回日本整形外科学会学術総会. 2010年5月.
戸口田淳也: 癌化と再生の接点としての組織幹細胞. 第69回日本癌学会学術総会. 2010年9月.
和田卓郎、他: 骨肉腫のペプチドワクチン療法. 第84回日本整形外科学会学術総会. 2011年5月.
田仲和宏、岩本幸英,他: JCOG骨軟部腫瘍グループにおける多施設共同臨床試験の実践体制. 第44回日本整形外科学会骨・軟部腫瘍学術集会. 2011年7月.
Y Iwamoto: Current status and perspectives on treatments for musculoskeletal sarcomas. Asia-pacific orthopaedic symposium in 2012 Annual Fall Congress of the Korean Orthopaedic Association. Oct 2012.